505 related articles for article (PubMed ID: 25003676)
1. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
2. Serum total antioxidant capacity to discriminate benign from malignant causes of biliary obstruction.
Beyazıt Y; Koçak E; Tanoğlu A
Turk J Gastroenterol; 2014 Oct; 25(5):592-3. PubMed ID: 25417631
[No Abstract] [Full Text] [Related]
3. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
[TBL] [Abstract][Full Text] [Related]
4. Author's reply: To PMID 25003676.
Ince AT
Turk J Gastroenterol; 2014 Oct; 25(5):593. PubMed ID: 25566599
[No Abstract] [Full Text] [Related]
5. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma--the influence of sampling time and hepatolithiasis.
Chen CY; Shiesh SC; Tsao HC; Lin XZ
Hepatogastroenterology; 2002; 49(45):616-20. PubMed ID: 12063953
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
[TBL] [Abstract][Full Text] [Related]
7. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis.
Alvaro D; Macarri G; Mancino MG; Marzioni M; Bragazzi M; Onori P; Corradini SG; Invernizzi P; Franchitto A; Attili AF; Gaudio E; Benedetti A
Ann Intern Med; 2007 Oct; 147(7):451-9. PubMed ID: 17909206
[TBL] [Abstract][Full Text] [Related]
8. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
[TBL] [Abstract][Full Text] [Related]
9. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
[TBL] [Abstract][Full Text] [Related]
10. Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer.
Chen WM; Wei KL; Chen YS; Chang PJ; Tung SY; Chang TS; Huang HC; Shen CH; Hsieh YY; Wu CS
World J Surg Oncol; 2016 May; 14():140. PubMed ID: 27142076
[TBL] [Abstract][Full Text] [Related]
11. Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Malignant and Benign Biliary Obstructions.
Abdel-Razik A; ElMahdy Y; Hanafy EE; Elhelaly R; Elzehery R; M Tawfik A; Eldars W
Am J Med Sci; 2016 Mar; 351(3):259-64. PubMed ID: 26992254
[TBL] [Abstract][Full Text] [Related]
12. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
Akdoğan M; Parlak E; Kayhan B; Balk M; Saydam G; Sahin B
Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
14. Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses.
Farina A; Dumonceau JM; Antinori P; Annessi-Ramseyer I; Frossard JL; Hochstrasser DF; Delhaye M; Lescuyer P
Biochim Biophys Acta; 2014 May; 1844(5):1018-25. PubMed ID: 23806607
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease.
Zabron AA; Horneffer-van der Sluis VM; Wadsworth CA; Laird F; Gierula M; Thillainayagam AV; Vlavianos P; Westaby D; Taylor-Robinson SD; Edwards RJ; Khan SA
Am J Gastroenterol; 2011 Sep; 106(9):1711-7. PubMed ID: 21670771
[TBL] [Abstract][Full Text] [Related]
16. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
[TBL] [Abstract][Full Text] [Related]
17. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
18. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
Nakeeb A; Lipsett PA; Lillemoe KD; Fox-Talbot MK; Coleman J; Cameron JL; Pitt HA
Am J Surg; 1996 Jan; 171(1):147-52; discussion 152-3. PubMed ID: 8554130
[TBL] [Abstract][Full Text] [Related]
19. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.
Qin XL; Wang ZR; Shi JS; Lu M; Wang L; He QR
World J Gastroenterol; 2004 Feb; 10(3):427-32. PubMed ID: 14760772
[TBL] [Abstract][Full Text] [Related]
20. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
